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Neoplastic disease and its therapeutic options have a huge impact on the patient’s quality of life from both the emotional and the
working point of view. The project “Il Corpo Ritrovato” aims at creating an interdisciplinary network of physicians to improve
the quality of life of the oncologic patient, focusing on such important aspects as dermocosmetological skin care but also on the
evaluation of new therapeutic and diagnostic algorithms in order to make further progress in the ﬁeld of prevention.
1.Introduction
Neoplastic disease and its therapeutic options have a huge
impact on the patient’s quality of life from both the emo-
tional and the working point of view [1]. Sociological rese-
arch has revealed that gender also plays an important role
in the emotional reaction to the disease [2, 3]. When faced
with a tumoral disease, men and women show signiﬁcantly
diﬀerent reactions: as wives and mothers are more subject
and vulnerable to stress, they present pluripathological situ-
ations more often than their partners and require more
frequent medical care.
Moreover, from a medical point of view, the short-term
modiﬁcations of the skin are the most evident and crippling
consequencesofchemotherapies,aboveallfromapsycholog-
ical point of view. Although chemotherapy contrasts cancer,
it often does not preserve good cells and organs, resulting in
a series of strongly crippling cutaneous alterations.
In chemotherapy treatment of some tumors (uterus,
ovary, breast), pharmacological damage is often potentiated
by hormonal “corrections” that aggravate the situation by
causing premature ageing compounded with the chrono-
logical and photo-induced process. This provokes serious
discomfort in female patients because of the aesthetic
modiﬁcations of their image.
The possibility to reduce hair loss and various nail alter-
ations or to improve skin colour, texture, and quality with
personalized cosmetic treatments, studied and structured for
speciﬁc skin types, can provide a comforting support for
female patients facing oncologic therapies.
We can also limit the negative eﬀects of radiotherapy tre-
atment by reducing cellular damage with the aid of applica-
tions, before and after the radiation session, of speciﬁc thera-
peuticandpreventiveaids.Itisalsoimportanttocontainany
destructivedamageandtoaddressthepreventionandcareof
cicatricial results.
These considerations have led to the birth of the project
“Il Corpo Ritrovato” and a scientiﬁc board (president: pucci
maria concetta romano; vice-president: gabriella fabbrocini;
secretary: Norma Cameli) with Lega Tumori (LILT) and un-
der the aegis of the Italian Ministry for Equal Opportunities.
The project aims at creating an interdisciplinary network of
physicians to improve the quality of life of the oncologic
patient, focusing on such important aspects as dermocos-
metological skin care but also on the evaluation of new2 ISRN Oncology
Table 1: Side eﬀects of chemotherapy.
Alopecia Flashing Itching Xerosis Neh Nail
disorder Rash Phototox Stomatitis Mucositis Vasculitis Oral
ulcers
Bleomicyn x x x x x x x
Bortezomib X
Busulfan x x x x
Capecitabine
Carboplatin x x x
Cetuximab x x
Cyclophosph-
amide xx x x xx
Cisplatin x
Cytarabine x x x
Chlorambucil x x
Dacarbazine x x
Dasatinib x
Docetaxel x x x x x x x
Doxorubicin x x x x x x
Epirubicin x
Erlotinib x
Etoposide x x x
Fludarabine
Flutamide x
Geﬁtinib
Gemcitabine x
Methotrexate x x x x
Mitomycin C x x
Nilotinib
Paclitaxel x X x x
Procarbazine x x
Sorafenib x
Tamoxifen x x
Topotecan x x
Vinblastine x
5-FU x X x x x
6
mercaptopurine x
Irinotecan x x
Imatinib
Vincristine x
Neh = neutrophilic eccrine hidradenitis.
therapeutic and diagnostic algorithms in order to make
further progress in the ﬁeld of prevention.
2. Chemotherapy and Skin
Chemotherapy causes several adverse events acting against
mucosa and cutis (Table 1) and adnexa, and many such reac-
tions are not known because of the continuous innovation in
thisﬁeld[4].Theantineoplasticdrugtargetsarekeratinocyte
mitotic activity in the epidermis and ﬁbroblasts, collagen
ﬁbres, and amorphous material in the derma.
At adnexa level, sudoriparous and sebaceous gland
regulation is aﬀected and hair trophism is involved. In the
pigmentary cells, there is melanocyte synthesis inhibition
and/or melanin anarchic synthesis. Keratinocytes lose their
form, mobility, cohesion, and division capability, result-
ing in slower epidermis turnover. The reticular dermis
reduces its thickness and diminishes its vascularization. TheISRN Oncology 3
Figure 1: Papular-pustular follicular rash during geﬁtinib therapy.
papillary dermis is characterized by matrix alterations with a
reduction in collagen, elastic ﬁbres, glycosaminoglycans, and
water. Furthermore, the recovery capability after pressure is
diminished (loose skin).
Moreover, iatrogenic and chronological ageing eﬀects
determine and increase wrinkles. Among the adnexa, the
numberandthefunctionalityofsudoriparousandsebaceous
glands are reduced with a consequential cutaneous dryness,
pore dilatations, and appearance of skin papulose lesions.
Hair follicles become terminal follicles.
In recent years, new classes of drugs used in oncology
have determined numerous and increasingly frequent skin
reactions. Such drugs include inhibitors of epidermal growth
factor receptor (EGFr), which is largely expressed by basal
keratinocytes, sebaceous cells, and endothelial cells [5].
The most frequently reported toxic cutaneous eﬀect
deriving from these drugs is the papulose pustulous follicle
rash, which is deﬁned as a form of acne since it involves
above all the face’s seborrhoeic areas, scalp, and chest,
and less frequently the extremities and the back. Such an
eruption appears during the ﬁrst two weeks of treatment,
accompanied by an extremely irritating pruritus and can be
complicated by bacterial overinfections, albeit short lived.
Its peculiar characteristic is the association of a typical
sebaceous gland disease with a marked xerosis, indicating
that the pathology protagonist is not the cutaneous adnexa
but the keratinocyte itself (Figure 1).
Mucosa and cutis xerosis, varying from the light to the
most marked forms with eczema and ﬁssures, has so far
shown a variable incidence from 12% to 35% in clinical trials
[6], and it often represents one of the cutaneous parameters
persistently inﬂuencing the patient’s life quality.
Onychopathologies (Figures 2 and 3), which are likewise
long lasting and thus highly crippling, can be found in 10–
20%ofpatientsunderoncotherapyandmayappearaboveall
as pigmentation alteration, onychodystrophies, paronychia,
onychocryptosis, and consequential recidivated or recurrent
onychomycosis.
The most widely recognized eﬀect that stigmatizes and
frightenstheoncologicpatientisalopeciainducedbychemo-
Figure 2: Fissures of ﬁnger tips during cetuximab therapy.
Figure 3: Pyogenic granuloma and nail infection during cetuximab
therapy.
therapic drugs. The incidence and extent of alopecia
vary according to the antineoplastic drug most frequently
employed, above all for taxanes, anthracyclines, and alky-
lating agents [7]( Table 2). It is generally a grave form of
scalp alopecia characterized by dystrophic eﬄuvium anagen
that appears in 1 to 8 weeks from the commencement of
chemotherapy, and it is usually reversible. However, cases
of permanent alopecia caused by chemotherapy are known,
associated above all with busulfan administration (50% of
patients) and radiation in doses > 700 Gy [8].
Other terminal hairs (beard, lash, eyebrow, pubic, and
axillary hairs) are interested by alopecia to varying degrees,
according to the percentage of those in anagen phase at the
beginning of the therapy and to the duration and posology
ofchemotherapictreatment.Moreover,otherhairalterations
may include isolated and slow hair growth, hair becoming
frizzier and curlier, trichomegaly, that is, excessive growth
of lash diameter and length, suggesting that the regulating
mechanismsatthebasisoftheseprocessesmayhavediﬀerent
pathogenetic origins.4 ISRN Oncology
Table 2: Antineoplastic drugs and alopecia.
Antineoplastic drugs that induce alopecia
frequently
Antineoplastic drugs that induce alopecia
sometimes
Antineoplastic drugs that induce alopecia
usually
Adriamycin Amsacrine Capecitabine
Cyclophosphamide Bleomycin Carmustine
Daunorubicin Busulfan Carboplatin
Docetaxel Cytarabine Cisplatin
Epirubicin 5-Fluorouracil Fludarabine
Etoposide Lomustine 6-Mercaptopurine
Ifosfamide Melphalan Procarbazine
Irinotecan Methotrexate Raltitrexato
Paclitaxel Mitoxantrone Streptozotocin
Topotecan Mitomycin C
Vindesine ThioTEPA
Vinorelbine Vincristine
Hypersensitivityreactions(urticaria,vasculitis,polymor-
phic erythema, Stevens-Johnson syndrome, etc.), ﬂashings,
and acral erythema, cutaneous pigmentation alteration,
mucosa inﬂammation (oral and anal), and photosensitivity
reactions are less frequent but no less important and require
a careful study in order to establish the most adequate
dermocosmetologic algorithm for each case.
3. Cutis and Radiotherapy
Nowadays, radiotherapy is a common therapeutic aid in
oncology,oneofthemorecommoncutaneoustoxiceﬀectsof
which is radiodermatitis. Indeed, about 85% of the patients
under radiotherapy develop skin manifestations which can
be related to this and range from a moderate erythematosus
rash to ulceration proper [9].
When this procedure is associated with a chemotherapic
algorithm, radiation recall and radiation enhancement can
add to the said skin lesions. Radiation recall is characterized
by the presence of an inﬂammatory reaction on a previously
irradiated area, after chemotherapic drug assumption. It
takes place within a few hours or days when the chemothera-
pic drugis administered from8to15days afterradiotherapy.
It is an erythematous rash that can be associated in diﬀerent
ways to vesiculation, scaling, and itching.
Radiation enhancement is the enhancement of skin tox-
icity deriving from radiotherapy caused by chemotherapic
drug administration, which may be contemporary or 7 days
after radiotherapy. The drugs more frequently involved in
such reactions are above all: bleomycin, doxorubicin, ﬂuo-
rouracil, hydroxyurea, 6-mercaptopurine, and methotrexate.
From a clinical point of view, it appears as radiodermitis,
with erythema, edema, vesicles, blisters, or erosions and
in severe cases with tissue necrosis which, unlike radiation
recall, can locally expand beyond the irradiated area.
Both manifestations present self-limitation over several
months,buttheyarestronglycripplingsincetheycansurvive
in long-term sequels like cutaneous atrophy, telangiectasia,
and ﬁbrotic results.
4. Dermocosmetologic Algorithm
The identiﬁcation and validation of guidelines to be used in
the elaboration of the ad hoc dermocosmetologic algorithm
for an oncologic patient represents an important supporting
instrument in the correct care of such a patient.
Moreover, in the pharmacological management of skin
toxicity reactions, there is a series of recommendations that
are quite empiric and not validated by evidence. They are
not yet used in daily clinic practice, do not involve speciﬁc
cosmetologicaspects,anddonotoﬀeranytherapeuticadvice
speciﬁc to the patient.
In any case, from the beginning of each treatment cycle,
the patient under oncologic treatment should adopt a series
of preventive behaviours and hygienic measures to counter
collateral eﬀects against cutis.
Our algorithm aims at keeping the various collateral
eﬀects under control, in terms of both prevention and thera-
peutic prescription.
4.1. Xerosis. In order to avoid this annoying eﬀect, it is nece-
ssarytopayattentionbothtocleansingandhydration.Deter-
gents with few or no aggressive surfactants and foaming
substances should be preferred (sodiolauril-sulfate, sodio-
lauriletere-sulfate) and an “aﬃnity” cleansing should be
preferred.
Therefore, W/O emulsions with lipid component char-
acterized by both natural vegetable fats (karit´ e, wheat
germ oil, jojoba, avocado) and synthetic ones (caprylic
capric triglyceride) should be recommended; on the otherISRN Oncology 5
hand, cosmetics with a large percentage of by-products of
hydrocarbons (petrolatum, paraﬃn wax, vaseline) and sil-
icones (cyclomethicone, dimethicone, cyclopentasiloxane,
cyclohexasiloxane)whichare,atpresent,consideredcarcino-
gensofseriesII,evenifnotsubjectedtoanyregulationonthe
allowed percentage, should be avoided.
The same can be said for the choice of cosmetics aiming
tore-establishhydrationandtoopposetheoxidativeeﬀectof
drug therapy.
The appropriate hydrating substance should contain
selected and active agents: unsaponiﬁable substances (karit´ e,
jojoba, olive, palm), aloe, niacinamide (vit. B3), tocopherols,
tocotrienols, ceramides, and gamma oryzanol.
The absence or minor presence of petrolatum and sili-
cones is important because hydration is not re-established by
mechanisms of maceration of the stratum corneum.
Exfoliating and irritating creams, for example glycolic
acid, alpha-hydroxy acids, and benzoyl peroxide or alcohol
gel formulations, are not recommended in this particular
period of skin fragility because of their drying and irritant
power.
If the itch is not tolerated, we can administer anti-H1
antihistamines (cetirizine, loratadine, fexofenadine).
Major xerosis can cause ulcerations and ﬁssures, for
which we can recommend the use of 2% eosin in local app-
lications together with creams or pastes based on vitamin
E and zinc oxide. The choice of an ointment formulation
(made from urea and not petrolatum), including that related
to topical antibiotics, should be always privileged.
4.2. Nail Damage. The prevention of onychopathology can
be aided by a special cooling glove [10], worn during the
infusion, which reduces the local toxicity of drugs due
to vasoconstriction induced by low temperature (up to
−25◦/−30◦C).
If there is nail infection, we should apply topical antisep-
tics to prevent overinfections as well as topic rifampicin and,
ifnecessary,topicalsilvernitratetoreducegranulationtissue.
In more serious cases, we can use oral antibiotics (doxy-
cyclineorminocycline)withoutanychemotherapyinterrup-
tionand,whenwesuspectabacterialorfungaloverinfection,
a cultural examination is important to establish the therapy.
4.3. Alopecia. Alopecia is certainly the most feared and
crippling mucocutaneous eﬀect caused by chemotherapy.
The use of topical 2% minoxidil seems to give good results
especially in the case of alopecia caused by taxanes and
anthracyclines, but it does not prevent alopecia caused by
doxorubicin [11]. Currently, preventive measures mainly
focus on scalp cooling. This is done either by procedures
in which the cooling agent (ice cap or gel cap) must be
changed several times or by continuous cooling of the scalp
withcoldairorcoldliquid.Therearetwoscientiﬁcrationales
for scalp cooling. The ﬁrst is vasoconstriction, which reduces
the blood ﬂow to the hair follicles during peak plasma
concentrations of the chemotherapeutic agents and so
reduces cellular uptake of these agents. The second rationale
is reduced biochemical activity, which makes hair follicles
less susceptible to the damage of chemotherapeutic agents.
The latter may be more important than vasoconstriction
[12]. However, further studies are needed to evaluate and
validate the evidence in this ﬁeld.
One of the objectives of the “Corpo Ritrovato” Scientiﬁc
Board is to intensify the research on the prevention of alope-
cia in oncology through topical, oral, and/or mechanical
resources.
The use of a wig by the cancer patient remains a valid aid
in case of hair and pigmentation trophic changes.
The wig should be free of adhesives, since these can
be irritating and sensitizing and with a texture suitable to
the needs of a sensitized and altered skin, as occurs during
chemotherapy.
Oftentheuseofbiologicaldrugsdoesnotleadtoalopecia
proper, but to massive hair loss which, however, does not
cause baldness. In these cases, lotions supplying active agents
to hair bulb and stimulating the skin microcirculation may
be necessary.
Supplements of antioxidants and substances dedicated to
the restoration of the physiological cycle of keratin (vitamin
E, melatonin, reduced glutathione, and other active agents in
the course of study) can be associated.
Hair dyes based on paraphenylenediamine are not rec-
ommended due to hair weakening while hair dyes based on
vegetable substances (although they are never 100%) can be
used as they cause only a minor contact sensitization in these
patients.
Permanent hair waves or pulling hair are not recom-
mended because of the resulting mechanical and chemical
stress (powerful oxidation).
4.4. Radiodermatitis. Radiodermatitis usually occurs when
the skin is exposed to higher doses than 2000cGy, while
the dryness associated with ﬂaking and itching is a frequent
event. Dermocosmetic care for this event is the same as that
described for the control of cleansing and hydration. The
dosage speciﬁes the application of cosmetic agents imme-
diately before and immediately after exposure to radiation
therapy.
A new series of antioxidants combined together in order
to form real dedicated cosmetics (holly, red vine, ubidecare-
none,Q10,extractsofparticularseaweed) arevery interesting.
4.5. Skin Rash and Folliculitis. Skin rash and folliculitis can
be considered real diseases rather than beauty ﬂaws. In some
cases, the eﬀectiveness of the antineoplastic agent is higher
if it produces folliculitis. In some tragic cases, the patient,
suﬀering from and distressed by this skin reaction, suspends
the therapy with the risk of not controlling the cancer
disease. In this event, the dermatologist plays a decisive
role, managing the disease and, at the same time, allowing
oncologists to continue the therapy.
The aﬀected skin should be cleansed gently and without
astringent agents, and it should be hydrated since xerosis
always accompanies folliculitis.
We have already mentioned unsaponiﬁable substances
of karit´ e, jojoba, and olive oil, but there are also sesame,
macadamia, and argan oils that, in addition to their hydrat-
ing power, also have anti-inﬂammatory action.6 ISRN Oncology
Topical antibiotics (gentamicin, clindamycin in combi-
nation with zinc oxide, mupirocin, and erythromycin) must
be chosen in greasy formulations (ointments or creams)
and used alternately with a daily dose. If the inﬂammatory
component is evident, a 1% hydrocortisone ointment can be
recommended in combination for the ﬁrst days of therapy.
During the skin reaction, dresses made of special anti-
inﬂammatory action ﬁbers, usually recommended for aller-
gic or atopic patients, can be helpful.
Inthepresenceofoverinfectiontheuseoforalantibiotics
maybenecessary(e.g.,tetracycline:doxycycline200mg/day).
Chemotherapy must be completely suspended in severe
cases with massive exfoliative and bullous components.
Eveninthiscase,ifdermatologicaltherapyisusedrapidly
with oncologic treatment, the damage can be signiﬁcantly
contained and the patient can complete pharmacological
cycles.
4.6. Scars. We can apply a cream made of hyaluronic acid,
muskrose,andhypericumoil1-2timesadayonpostsurgical
scars, so as to improve the elasticity of the tissue and to
reduce inﬂammation. The use of creams, formulated with
allium bulb stock extract, makes scars softer and smoother.
Radiotherapy, which is often performed on the scar
area, paradoxically improves the scar’s cosmetic appearance,
causing atrophy. Thus, the scar area must be controlled
through careful hydration and photoprotection.
The choice of garments to wear and the detergents
to prefer is an important detail to protect a weak skin
from irritant and external insults. The garments to wear on
skin are completely natural (cotton, linen, silk) and with
vegetable colors. Synthetic and elastic garments, rough wool,
or clothing with metal and sequins should be avoided.
4.7. Photoprotection. both radiation therapy and some che-
motherapy medications (5-ﬂuorouracil, vinblastine, dacar-
bazine) can cause photosensitivity, so it is important to be
careful to protect skin during treatment. Direct sunlight
during midday must be avoided, and hats and umbrellas
should be used to shelter yourself. Tanning beds must be
avoided. Some sunscreens can contain irritating chemicals
and for this reason sun block should be preferred, as
zinc oxide, for maximum protection. We should choose
physical sun ﬁlters, applied 1-2 hours before sun exposure
(the chemical ﬁlters may occur contact sensitization). Fatty
compounds and formulations should be avoided for their
occlusive potential and the risk of developing reactive
folliculitis. Treatments that may be recommend are local
corticosteroids and emollient lotions for itching. If a reaction
is severe, systemic corticosteroids may be prescribed.
5. Conclusions
The chance of surviving cancer is both an achievement
and a reality of our time. Currently, the synergy between
early diagnosis and various combined and personal therapies
(surgery, radiation, chemotherapy) has reduced mortality
in a signiﬁcant number of cases, but this is not always
accompanied by a satisfactory life quality.
The objective of the project “Corpo Ritrova,to” a scien-
tiﬁc board for research and studies on dermocosmetological
skin care of oncologic patients, is to give new life to a ruined
body, caring for and protecting it at the same time as it
undergoes oncologic therapy.
Hence, the project objective is to improve the quality of
life, health, and beauty for those who might suﬀer or are
already suﬀering from cancer, and it can represent a further
important aid for the oncologic patient.
In this diﬃcult time, it is essential not to lose control
and perception of one’s own body and to continue to receive
treatments of serious and competent specialists, maintaining
a good self-esteem and satisfaction.
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